LLM Economics: Cloud vs. On-Premise for Hospital AI Profitability

The hype around generative AI in healthcare, especially the ambient clinical scribe, is deafening. Everyone’s talking about a future with zero documentation burden and happy doctors. But the stampede to deploy these tools is ignoring the bill that’s coming due. I’m talking about the real operational cost, especially the dependency on cloud infrastructure and APIs. For any growth equity investor or analyst trying to figure out the actual margins of a gen-AI startup, getting into the weeds on these economics isn’t just important, it’s everything. This is a breakdown of the operational margins for clinical Large Language Models (LLMs), looking at cloud-hosted APIs versus local, on-premise setups to figure out what gross margins are actually achievable.

The Hidden Costs Behind Apparent AI Gross Margins

Those 90% software gross margins you hear about are a fantasy when you’re paying huge, recurring third-party costs. For ambient clinical intelligence, that cost is the LLM inference itself. You’re either paying an API fee to a major cloud provider for every clinical note, or you’re running it on your own expensive, local hardware. That choice dictates your entire cost structure and whether you can ever scale profitably. Think about it: an enterprise LLM’s API fees can eat a seemingly healthy software margin alive. Every single patient encounter that gets transcribed and summarized is another per-token or per-call charge. One call is cheap, sure. But multiply that by thousands of clinicians seeing dozens of patients a day across an entire hospital system, and you’ve got a massive operational expense on your hands. It’s an especially big problem for companies that just put a wrapper around a general-purpose LLM without doing any of their own model optimization.

Cloud-Hosted vs. On-Premise LLM Deployment: A Margin Headwind

You either go with a cloud API or you build it yourself. It’s a huge decision for AI health companies and their hospital clients, and it hits gross margins directly. Cloud solutions get you up and running fast. The problem is they come with a variable cost that’s tied to every single API call. Abridge, which became Epic’s first ‘Pal’ and integrates deeply with Epic Systems EHR, is a great example of a company using cloud infrastructure for its ambient documentation. They’ve raised over $800 million (including a $300 million Series E in June 2025 and a $316 million Series E extension in April 2026) and are in over 250 health systems. The hospital avoids a big upfront check, but they’re stuck with an operating expense that never goes away and has to be baked into the price. Nuance, the Microsoft-backed incumbent with its DAX solution, does the same thing on Microsoft Azure, getting the benefit of scale but also paying the associated usage costs you can see on their Microsoft Azure AI pricing page. And don’t forget, rolling out an ambient scribe system hospital-wide takes months, no matter the deployment strategy, requiring a ton of project management to integrate with existing Epic App Orchard documentation and workflows. On the other hand, going local with an on-premise deployment means a huge capital expense for GPUs and servers, not to mention the specialized engineers to run the whole thing. You kill the per-API call fees, but now you’re paying for depreciation, power, and constant maintenance. Plus, you have to make the whole thing compliant with the HIPAA Security Rule on your own hardware, which is a massive headache and expense. For a hospital, it comes down to weighing a predictable capital expenditure against a variable operational one, and asking honestly if their IT department can even handle it.

Enterprise Contract Breadth and Health Plan Penetration as Valuation Signals

For growth equity investors, cool technology doesn’t set a pre-IPO company’s valuation floor. Demonstrable commercial traction does. How can you tell if they have it? You need to see two things: broad enterprise contracts and some penetration with health plans. These are the real signals that a company can generate sustainable revenue and actually scale. Companies that have landed big contracts with major hospital systems, especially ones that plug right into a dominant EHR platform like Epic Systems, are showing they have a real path to adoption. Abridge’s deep integration as Epic’s first ‘Pal’ is a perfect example, proving they have a low-friction way to get installed in a hospital’s existing IT setup. Well-documented APIs make these integrations cheaper and faster for everyone involved. Getting health plans on board is a different, but equally important, signal. It might be less direct for a scribe tool, but it shows the broader healthcare system accepts the value proposition. When a solution can prove it improves outcomes or reduces costs, payers take notice, and that can eventually create new reimbursement pathways or get you preferred vendor status. It’s not always a direct line to revenue, but it’s what gives a company long-term market relevance.

Outcomes Publication History: The Evidence Base for ROI

In healthcare, you’re nothing without clinical evidence. For a generative AI startup, a strong history of publishing outcomes is a powerful commercial advantage that significantly de-risks the investment for people writing the checks. This is just good practice, aligning with the GMLP (Good Machine Learning Practice) principles that call for real-world evidence and performance monitoring. Startups with peer-reviewed papers or solid internal studies proving their tool improves physician efficiency, reduces burnout, or makes documentation more accurate will always command a higher valuation. Those published outcomes are the concrete proof of ROI that hospital CFOs need to see, which shortens the sales cycle and makes the contracts stick. Without that evidence, you’re just another piece of unproven tech stuck in pilot purgatory, as hospital CIOs consistently point out in KLAS Research reports on healthcare IT adoption.

Prioritizing Startups with Proprietary Model Optimization and Direct EHR Partnerships

Given the brutal economics of LLM deployment, investors should be looking for two things: proprietary model optimization and deep, direct EHR partnerships. Optimizing your own models means you’re not chained to expensive, generic third-party APIs. By fine-tuning smaller, purpose-built models on specific healthcare data, a company can slash its per-transaction costs, which directly expands its gross margins. This also builds a strong data moat over time, as their models become exceptionally good at very specific healthcare tasks that a general model can’t match. Direct partnerships with an EHR giant like Epic Systems are the other key. These relationships simplify integration and offer a direct sales channel to a massive, established customer base. Being embedded within the Epic App Orchard, for instance, means a startup benefits from pre-built technical connections and a trusted brand which dramatically lowers the friction of enterprise sales. This is how you avoid becoming a “zombie company”, one with promising tech but no ability to close enterprise deals. The government gets this too. The Office of the National Coordinator for Health Information Technology (ONC) is constantly pushing for this kind of interoperability, making deep EHR integration a non-negotiable for any tool that wants to be widely adopted, as outlined in their ONC interoperability initiatives.

Methodology and Source Note

A quick note on the model here. The financial analysis is based on public pricing sheets from cloud providers for LLM API access and enterprise-grade hardware. This was cross-referenced with industry benchmarks for healthcare IT integrations. For the on-premise cost estimates, I’m factoring in the typical costs for hardware acquisition, installation, power, and ongoing maintenance, along with the salary costs for the specialized engineers required to manage it all. These benchmarks are pulled from public financial disclosures of comparable tech companies and from conversations with hospital IT leaders. While the exact numbers will obviously fluctuate with specific vendor contracts and scale, the relative cost structures and their effect on margins are consistent. The goal is to give growth equity investors a solid framework for judging the real economic viability of pre-IPO AI health companies in this space.